SESSION TYPE: Lung Cancer Posters II
PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM
PURPOSE: Lung cancer has highest mortality among cancer in Korea. In advanced nonsmall cell lung cancer (NSCLC), major therapeutic modality is chemotherapy. With the progression of lung cancer, second line chemotherapy is demanded. However, there is a controversy about 2nd-line chemotherapy in terms of selection of chemotherapeutics, number of cycles, and response rates. Even numbers of clinical trials has been done for the effect of 1st-line chemotherapy, the study of 2nd-line chemotherapy is limited. The objective of this study is the analysis of determinants on the success of 2nd-line chemotherapy in advanced non-operable NSCLC.
METHODS: The patients’ records were reviewed retrospectively from 2005 to 2011 in Ewha Medical Center, Seoul, Korea. Included 87 patients were non-operable cases of stage III-IV NSCLC, received 2nd-line chemotherapy. The patients were divided into two groups: 47 subjects of successful chemotherapy, defined as more than 3 cycles (success group) and 40 subjects of unfavorable chemotherapy, defined as below 3 cycles (failure group).
RESULTS: Success in 2nd-line chemotherapy was not affected from baseline BMI, gender, smoking, albumin level, lung function, platinum based chemotherapy in 1st-line, duration of 1st-line, use of newer chemotherapeutics in 1st-line, T stage, M stage, histology of adenocarcinoma, and previous radiotherapy to lung. Only, Age and N stage were different significantly between 2 groups. Success group showed better survival (21±12mo) than failure group (13±10mo).
CONCLUSIONS: Relatively younger age and less N stage regardless of previous therapeutic condition are most important determinants on the success of 2nd-line chemotherapy, which affects to survival directly in advanced non-operable NSCLC.
CLINICAL IMPLICATIONS: Successful 2nd-line chemotherapy is very difficult in advanced lung cancer. It guides an implication of effectiveness and prognosis prior to 2nd-line chemotherapy with the consideration of age and N stage.
DISCLOSURE: The following authors have nothing to disclose: Seok Jeong Lee, Hyun Ju Kang, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang
No Product/Research Disclosure InformationMokdong Hospital Ewha Womans University, Seoul, Republic of Korea